| Theme | Problems to be solved in the therapy for renal anemia : Association of ESA hyporesponsiveness with dysregulated iron metabolism | |
|---|---|---|
| Title | Current status of renal anemia treatment with diversified erythropoiesis stimulating agents | |
| Publish Date | 2013/12 | |
| Author | Hirokazu Honda | Department of Nephrology, Showa University School of Medicine |
| [ Summary ] | Since renal anemia in chronic kidney disease (CKD) primarily develops from decreased renal synthesis of erythropoietins, treatment which regulates erythropoiesis stimulating agents (ESA) is required to manage renal anemia. In Japan, recombinant human erythropoietin (rHuEPO) as the first generation of ESA was first used for practical applications in treating renal anemia in 1990. Long acting ESAs are now widely used. Biosimilar forms of rHuEPO are available for treatment of renal anemia. Because of these advances, ESA therapy for treatment of renal anemia has evolved another step. | |